Sinco Pharmaceutical Holdings (HKSE:06833) GF Score: 44/100 (As of Aug. 28, 2026) — 16% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06833 Sinco Pharmaceutical Holdings Ltd HKSE:06833
44 GF Score
Price HK$0.17
GF Value HK$0.19
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sinco Pharmaceutical Holdings GF Score?

Sinco Pharmaceutical Holdings HKSE:06833 -0.60% 44 GF Score is 44 as of Aug. 28, 2026, which is 16% above its 10-year median of 38.00. GuruFocus rates HKSE:06833 with a GF Score™ of 44/100 and a GF Value™ of HK$0.19 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Sinco Pharmaceutical Holdings has the GF Score of 44, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 6/10
3. Growth Rank : 4/10
4. GF Value Rank : 0/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Sinco Pharmaceutical Holdings might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Sinco Pharmaceutical Holdings  (HKSE:06833) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Sinco Pharmaceutical Holdings GF Score Related Terms

HKSE:06833 vs MCK, COR, CAH: GF Score Comparison

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinco Pharmaceutical Holdings GF Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's GF Score falls into.


HKSE:06833
44GF Score
Sinco Pharmaceutical Holdings Ltd HKSE:06833
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 44 mean?
Sinco Pharmaceutical Holdings (HKSE:06833) has a GF Score of 44 as of Aug. 28, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sinco Pharmaceutical Holdings and its competitors. This is 16% above median its historical median of 38.00. Over the past decade, Sinco Pharmaceutical Holdings' GF Score has ranged from 7.00 to 54.00.
Is Sinco Pharmaceutical Holdings' GF Score too high?
Sinco Pharmaceutical Holdings' current GF Score of 44 is 16% above median its 10-year median of 38.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 54.00. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' GF Score compare to MCK and COR?
Sinco Pharmaceutical Holdings' GF Score of 44 can be compared against companies in the Medical Distribution industry. Historically, Sinco Pharmaceutical Holdings' own GF Score has ranged from 7.00 to 54.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Distribution company?
A good GF Score depends on the Medical Distribution industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sinco Pharmaceutical Holdings and its competitors. Sinco Pharmaceutical Holdings's current GF Score is 44, which is 16% above median its own 10-year median of 38.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current GF Score is 44, which is 16% above median its 10-year median of 38.00. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current GF Score is 44 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?

Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19. GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.

Key valuation signals for HKSE:06833:

  • GF Score: 44 (16% above median its 10-year median of 38.00)
  • GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinco Pharmaceutical Holdings Business Description

Address No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score

Get the complete analysis for HKSE:06833

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.17
Price
HK$0.19
GF Value